Tackenberg B, Schneider-Hohendorf T, Müller A, Schodrowski J, Wiendl H
Klinik für Neurologie, Bereich Neuroimmunologie, AG Klinische Neuroimmunologie, Philipps-Universität und Universitätsklinikum Marburg, Baldingerstr. 1, 35043, Marburg, Deutschland,
Nervenarzt. 2014 Oct;85(10):1255-62. doi: 10.1007/s00115-014-4062-2.
The immunotherapy of multiple sclerosis (MS) is currently one of the most dynamic fields in clinical neurology. The comprehensive number of well-established and new innovative treatment options are a challenge for an intensive preoccupation with the differential indications and an activity-driven treatment control. In this context this review summarizes the known predictors of the natural course of MS and gives a review of challenges to be expected in association with predictors of treatment control.
多发性硬化症（MS）的免疫疗法目前是临床神经学中最具活力的领域之一。大量成熟的和新的创新治疗选择，对于深入关注鉴别适应症以及以活性为导向的治疗控制而言是一项挑战。在此背景下，本综述总结了MS自然病程的已知预测因素，并对与治疗控制预测因素相关的预期挑战进行了综述。
